Genetics and Cancer

The Cell and Gene Therapy Catapult (CGT Catapult), an independent innovation and technology organisation specialising in the advancement of cell and gene therapies, has opened a facility in the Edinburgh BioQuarter, its first site in Scotland.

A new drug candidate for hard-to-treat cancers, discovered at the University of Edinburgh and licensed by biopharmaceutical company Nuvectis Pharma, Inc., has received US Food and Drug Administration (FDA) clearance to proceed to clinical trials.

BioCaptiva has announced an oversubscribed £2.1 million additional seed financing to complete the first in-human trial with the BioCaptis.

Kynos Therapeutics, a spinout company launched with Edinburgh Innovations' support, has raised £9 million to progress development of therapies at the interface of inflammation, immunity and metabolism.

Edinburgh Innovations clients have scooped two of the four Scottish AccelerateHER Awards 2022 for inspiring female founders.

Scientists at the University of Edinburgh have launched a spinout company that aims to democratise genetic data access and cut from days to minutes the time it takes to analyse millions of genetic records.

An Edinburgh researcher working to develop new therapies for difficult-to-treat cancers is among the first recipients of funding from the $20 million beLAB1407, recently launched to advance life sciences innovation.